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Abstract In adult inflammatory bowel disease (IBD) pa-
tients, there is a strong discrepancy between symptoms
and biomarkers of inflammation. Data on pediatric IBD
patients are conflicting. Therefore, we aimed to investi-
gate the relationship between clinical symptoms and bio-
markers of inflammation in pediatric IBD. Patients aged
<18 years with previously diagnosed Crohn’s disease
(CD) or ulcerative colitis (UC) were included. Clinical
disease activity was determined using the abbreviated
Pediatric CD Activity Index (aPCDAI) or Pediatric UC
Activity Index (PUCAI). Biochemical disease activity
was assessed using fecal calprotectin (FC) and C-
reactive protein (CRP). In total, 127 patients (62 male;
median age 14.9 years) were included (82 CD, 45 UC).
FC correlated weakly with total aPCDAI score (rs = 0.32;
95 % CI 0.12–0.51; p = 0.003) and total PUCAI score
(rs = 0.36; 95 % CI 0.07–0.62; p = 0.015). Only aPCDAI
components abdominal examination and perirectal disease
and PUCAI component activity level had a significant
correlation with levels of FC. CRP correlated weakly with
total aPCDAI score (rs = 0.28; 95 % CI 0.05–0.46;
p = 0.012) and aPCDAI components abdominal examina-
tion and activity level. No significant correlation was ob-
served between CRP and total PUCAI score (rs = 0.01;
95 % CI −0.34–0.29; p = 0.961) or individual PUCAI
components.
Conclusion: There is a strong discrepancy between clinical
symptoms and biomarkers of inflammation in children with
IBD.
What is Known:
• A substantial proportion of asymptomatic pediatric inflammatory bowel
disease (IBD) patients have elevated biomarkers of inflammation.
• There is a strong discrepancy between symptoms and biomarkers of
inflammation in adults with IBD.
What is New:
• Clinical symptoms are only weakly associated with levels of fecal
calprotectin and serum C-reactive protein in children and adolescents
with previously diagnosed IBD.
• Similarly to adult IBD patients, there is a strong discrepancy between
clinical symptoms and biomarkers of inflammation in children with
IBD.
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Introduction
Traditionally, treatment of inflammatory bowel disease (IBD)
was mainly guided by symptoms such as abdominal pain,
bowel habits, and general well-being. Symptomatic treatment,
however, may not improve long-term outcome or slow disease
progression [27], possibly because symptoms may not accu-
rately reflect the underlying inflammatory process [19].
Therefore, mucosal healing (often defined as the complete
resolution of macroscopic inflammation on endoscopy) is in-
creasingly advocated as a therapeutic target in IBD [27].
Indeed, mucosal healing is a predictor of long-term outcome
of both Crohn’s disease (CD) and ulcerative colitis (UC) [31,
32]. However, due to its invasiveness and costs, endoscopy is
not ideal for frequent monitoring of disease activity.
Therefore, in current practice, biomarkers such as fecal
calprotectin (FC) and serum C-reactive protein (CRP) are fre-
quently used as surrogate markers of endoscopic IBD activity.
Especially, levels of FC have a strong correlation with endo-
scopic disease activity [26, 7, 6, 36]. It can, however, be ar-
gued that complete normalization of FC—potentially indicat-
ing complete resolution of macroscopic and microscopic in-
flammation—is a therapeutic target beyond mucosal healing.
In support of this, recent studies in adults have shown that
even in the absence of endoscopic signs of disease activity,
levels of FC are predictive of long-term outcome [28, 20].
Furthermore, a therapeutic algorithm based on levels of FC
alone did improve medium-term outcome in adults with IBD
[24, 26]. However, the optimal target of treating IBD remains
to be established, and a gold standard for monitoring IBD is
currently not available [26].
A substantial proportion of asymptomatic pediatric IBD
patients have elevated biomarkers of inflammation [35].
Data on adult IBD patients indeed indicate that there is a
strong discrepancy between clinical symptoms and biochem-
ical markers of inflammation [3, 36]. Data on pediatric IBD
are conflicting, with reported correlations between symptoms
and FC levels ranging from absent (r = 0.0) [12, 33] to strong
(r = 0.7) [13] in CD and from weak (r = 0.3) [15] to strong
(r = 0.8) [2] in UC.
We aimed to investigate the relationship of clinical symp-
toms with biochemical markers of inflammation in a random
sample of children and adolescents who were previously di-
agnosed with and treated for IBD.
Methods
Patients
In this cross-sectional, observational study, we aimed to in-
clude children and adolescents (aged <18 years) with an
established diagnosis of CD or UC according to revised
Porto criteria [17], who visited the outpatient pediatric gastro-
enterology clinic of the Emma Children’s Hospital/Academic
Medical Center, Amsterdam, the Netherlands. Patients with
IBDU, an ileo- or colostomy, or a colectomy with ileal
pouch-anal anastomosis were excluded. Approval from the
local Medical Ethics Review Committee was obtained.
Data collection
Patient characteristics were obtained from patients’ medical
records, including age, sex, age at diagnosis, disease duration,
disease location and behavior, the presence of (previous)
growth impairment, current medication, and previous IBD-
related surgery. Paris classification was used to classify IBD
phenotype [16].
Clinical disease activity was determined using the Pediatric
Ulcerative Colitis Activity Index (PUCAI) for UC patients
[37] or the abbreviated Pediatric Crohn’s Disease Activity
Index (aPCDAI) for CD patients (Online Resource) [18, 34].
The PUCAI consists of six clinical items, with scores ranging
from 0 to 85, with cutoff scores for remission (<10 points),
mild (10–34), moderate (35–64), and severe disease (≥65)
[37]. The aPCDAI consists of six clinical items, with scores
ranging from 0 to 70, with cutoff scores for remission (<10
points), mild (10–25), moderate (26–39), and severe disease
(≥40) [34, 18].
Biochemical disease activity was assessed using FC and
serum CRP levels at the time of assessing clinical disease
activity. Fecal calprotectin concentrations were measured
using an enzyme-linked immunosorbent assay (Bühlmann
Laboratories, Switzerland). The respective lower and upper
limits of detection were 0 and 1800 μg/g. For the assessment
of biochemical remission, previously suggested cutoff levels
of <250 μg/g [7] for FC and <5 mg/L [21] for CRP were used
(FC-based remission and CRP-based remission, respectively).
For exploratory analyses, different FC cutoff levels of <50μg/g
[21] and <1000 μg/g were used.
Sample size
Sample size calculation was based on the power to detect a
correlation coefficient that we considered clinically
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meaningful (r ≥ 0.5, resulting in an explained variance
≥25 %). A two-sided Fisher’s z test with an alpha of 0.05 will
have 90 % power to detect a Pearson’s correlation coefficient
of 0.5 when the sample size is 38. Accounting for non-
parametric testing (15 %), we aimed to include at least 44
CD patients and 44 UC patients.
Statistical analysis
Primary analysis was the correlation between levels of
FC and clinical indices. Secondary analyses included
the correlation between levels of CRP and clinical indi-
ces and the correlation of both biomarkers with individ-
ual components of disease activity indices. Continuous
data with a non-normal distribution were reported using
medians and interquartile ranges (IQR). Mann–Whitney
U tests were used to compare differences between
groups, and Spearman’s rank correlations were used to
investigate the relation between two parameters with
95 % confidence intervals (CIs) based on bootstrapping
with 1000 samples with the same size as the original
sample with replacement. The null hypothesis (no corre-
lation between clinical symptoms and biochemical
markers of inflammation) was rejected if the 95 % CI
of the Spearman’s rank coefficient (rs) did not include
0. Categorical/dichotomous data were reported as per-
centages, and Fisher’s exact tests were used to compare
differences between groups. Point-biserial correlations
were used to investigate the relation between continuous
and dichotomous outcomes. Significance was set at
p < 0.05. Statistical analysis was performed using IBM
SPSS Statistics 22 for Windows.
Results
Patient characteristics
Between March 2014 and March 2016, a total of 127 patients
(49 % male) with a median age of 14.9 years (IQR 13.5–16.4)
were included, 82 with a diagnosis of CD and 45 with a diag-
nosis of UC (Table 1). Based on clinical indices, 79 (63 %)
patients were in remission (CD 54 [66 %]; CU 25 [56 %]), 42
(33 %) patients had mild disease activity (CD 27 [33]%; UC
15 [33 %]), and 6 (5 %) patients had moderate disease activity
(CD 1 [1 %]; UC 5 [11 %]). No patients had severe disease
activity at the time of evaluation.
In total, 48 (38 %) patients were in FC-based remis-
sion, of whom 13 (27 %) had clinically active disease. An
overview of these patients’ symptoms is provided in the
Online Resource.
Biochemical markers in Crohn’s disease
Fecal calprotectin
The median FC level in patients with CD was 260 μg/g (IQR
76–1297; range 1–1800μg/g). The proportion of patients with
CD in FC-based remission was 50 %. The proportion of pa-
tients with CD in clinical remission with FC-based remission
was highly dependent on the cutoff for biochemical remission
and was higher compared to patients with clinically active
disease (Table 2). Fecal calprotectin had a weak but significant
positive correlation with the total aPCDAI score (rs = 0.32
[95 % CI 0.13–0.49]; p = 0.003; Fig. 1a). Furthermore, FC
levels had a weak positive correlation with the aPCDAI compo-
nents abdominal examination (rs = 0.23 [95 % CI 0.02–0.40];
p = 0.037) and perirectal disease (rs = 0.23 [95%CI 0.10–0.34];
p = 0.036; Table 3).
C-reactive protein
The median CRP level in patients with CD was 1.3 mg/L
(IQR 0.4–5.0; range 0.3–44.0 mg/L). The proportion of
CD patients in CRP-based remission determined with
CRP was 73 %. Crohn’s disease patients in clinical remis-
sion were more frequently in CRP-based remission, com-
pared to patients with active disease (Table 2). C-reactive
protein had a weak positive correlation with the total
aPCDAI score (r s = 0.28 [95 % CI 0.05–0.46];
p = 0.012; Fig. 1b). Furthermore, CRP levels had a weak
positive correlation with the aPCDAI components abdom-
inal examination (rs = 0.33 [95 % CI 0.14–0.48];
p = 0.003) and patient functioning (rs = 0.24 [95 % CI
0.01–0.45; p = 0.028; Table 3). In CD patients, CRP
levels had a moderate positive correlation with FC levels
(rs = 0.459 [95 % CI 0.27–0.62]; p < 0.001).
Biochemical markers in ulcerative colitis
Fecal calprotectin
The median FC level in patients with UC was 398 μg/g (IQR
73–1290; range 1–1800μg/g). The proportion of patients with
UC in FC-based remission was 40%. Similar to the analysis in
CD, the proportion of patients with UC in clinical remission
with FC-based remission was highly dependent on the cutoff
for biochemical remission. However, no significant difference
was found in biochemical remission rate between patients
with and without clinically active disease (Table 2). Fecal
calprotectin had a weak positive correlation with the total
PUCAI score (rs = 0.36 [95 % CI 0.07–0.61]; p = 0.015;
Fig. 2a and Table 3). Furthermore, the activity level compo-
nent of the PUCAI had a moderate positive correlation with
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levels of FC (rs = 0.46 [95 % CI 0.20–0.68]; p = 0.001;
Table 3).
C-reactive protein
The median CRP level in patients with UC was 1.5 mg/L
(IQR 0.5–4.2; range 0.1–22.2 mg/L). The proportion of
UC patients in CRP-based remission was 78 %. There
was no difference in the proportion of patients in CRP-
based remission, in patients with or without clinically ac-
tive UC (Table 2). No significant correlation was ob-
served between the total PUCAI score (rs 0.01 [95 % CI
−0.34–0.30]; p = 0.961) or individual PUCAI components
and CRP levels (Fig. 2b and Table 3). In UC patients,
CRP levels showed no significant correlation with FC
levels (rs = 0.09 [95 % CI −0.21–0.39]; p = 0.542).
Discussion
In this study, we evaluated the relationship of biomarkers of
disease activity with clinical symptoms in children and ado-
lescents who were previously diagnosed with IBD. In both
CD and UC patients, the total disease activity index score
had a weak positive correlation with FC levels. Only the
aPCDAI components abdominal examination and perirectal
Table 1 Patient characteristics
CD (n = 82) UC (n = 45)
Age (median, IQR) 15.0 (13.1–16.6) 14.2 (11.4–16.7)
Males (n, %) 43 (52 %) 19 (42 %)
Months since diagnosis of IBD (median, IQR) 26.1 (9.8–39.1) 22.4 (7.6–43.6)
Current medication for IBD (n, %) 77 (93 %) 43 (96 %)
• Anti-TNF (n, %) 32 (39 %) 2 (4 %)
• Steroids (n, %) 7 (9 %) 9 (20 %)
• Thiopurine (n, %) 36 (44 %) 16 (36 %)
• Methotrexate (n, %) 8 (10 %) 0 (0 %)
• 5-ASA (n, %) 9 (11 %) 37 (82 %)
Previous IBD-related surgery (n, %) 12 (15 %) 1 (2 %)
• Perianal surgery (n, %) 7 (8 %) 0 (0 %)
• Resectional surgery (n, %) 5 (6 %) 1 (2 %)
CD: age at diagnosis (Paris classification)
• A1a 0–<10 years (n, %) 25 (30 %)
• A1b 10–<17 years (n, %) 57 (70 %)
• A2 17–40 years (n, %) 0 (0 %)
CD: locationa (Paris classification)
• L1 (n, %) 7 (9 %)
• L2 (n, %) 24 (29 %)
• L3 (n, %) 49 (60 %)
• L4a (n, %) 34 (41 %)
• L4b (n, %) 3 (4 %)
• L4ab (n, %) 1 (1 %)
CD: behavior (Paris classification)
• B1 non-structuring, non-penetrating (n, %) 69 (84 %)
• B2 structuring (n, %) 7 (9 %)
• B3 penetrating (n, %) 5 (6 %)
• B2B3 penetrating and structuring (n, %) 1 (1 %)
• p perianal disease (n, %) 13 (16 %)
CD: growth impairment (Paris classification)
• Evidence of growth delay (n, %) 14 (17 %)
CD: aPCDAI (median, IQR) 5 (0–10)
UC: extent (Paris classification)
• E1 proctitis (n, %) 5 (11 %)
• E2 left-sided disease (n, %) 11 (24 %)
• E3 extensive disease (n, %) 6 (13 %)
• E4 pancolitis (n, %) 23 (51 %)
UC: severityb (Paris classification)
• S1 ever severe (n, %) 9 (20 %)
UC: PUCAI (median, IQR) 5 (0–15)
aPCDAI abbreviated Pediatric Crohn’s Disease Activity Index, CD Crohn’s disease, PUCAI Pediatric Ulcerative
Colitis Activity Index, UC ulcerative colitis
a L1 distal 1/3 ileum ± limited cecal disease, L2 colonic, L3 ileocolonic, L4a upper disease proximal to ligament of
Treitz, L4b upper disease distal to ligament of Treitz and proximal to distal 1/3 ileum
bDefined as ever a PUCAI ≥65 points
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disease and the PUCAI component activity level correlated
significantly with FC levels, albeit weakly. In CD patients,
CRP had a weak positive correlation with the total aPCDAI
score and the aPCDAI components abdominal examination
and patient functioning. In UC patients, CRP did not correlate
with total disease activity index score nor with its individual
components.
The correlation between FC levels and the total aPCDAI
score in this study is lower than the correlation of FC levels
with the original Pediatric Crohn’s Disease Activity Index
(PCDAI) that is reported in previous studies [1, 9, 10, 15,
13], although results have not been unequivocal [4, 33]. This
may be related to the fact that the aPCDAI consists only of
clinical components, as opposed to the original PCDAI, which
also includes laboratory parameters. The exclusion of these
additional parameters from the clinical disease activity score
may have reduced the correlation with FC levels, since they
are known to correlate with FC levels [7]. In this study, we
chose to use the aPCDAI because it is a measure of purely
clinical disease activity, as opposed to the original PCDAI.
Of the individual aPCDAI components, only abdominal
examination and perirectal disease correlated with FC levels.
This may be explained by the more objective nature of these
observations, compared to the more subjective components
such as abdominal pain and patient functioning. However, in
studies of adults with CD, no correlation was found between
FC levels and perirectal disease [30]. In addition, the more
objective component stool consistency of the aPCDAI was
not related to levels of FC. Surprisingly, activity level, argu-
ably the most subjective component of the PUCAI, was the
only component that correlated significantly with FC level.
Similarly, activity level expressed as the level of experienced
fatigue was previously found to correlate positively with
levels of biochemical disease activity in adult IBD patients
[42].
Overall, only a weak correlation was found between clini-
cal disease activity and levels of FC, probably the most sen-
sitive currently available marker for gastrointestinal inflam-
mation in IBD. Even the upper limits of the 95 % CIs of the
correlation coefficients (0.51 for CD and 0.62 for UC) indicate
that, at most, only a small proportion (respectively, 26 and
Fig. 1 a Fecal calprotectin and b C-reactive protein levels by clinical
disease activity as assessed by aPCDAI
Table 2 The distribution of
biochemical disease activity in
clinical remission or active
disease
CD Clinical remissiona (n = 54) Active diseaseb (n = 28) p value
FC < 50 μg/g 15 (28 %) 1 (4 %) 0.008
FC < 250 μg/g 34 (63 %) 7 (25 %) 0.002
FC < 1000 μg/g 43 (80 %) 15 (54 %) 0.021
CRP < 5 mg/L 45 (83 %) 15 (54 %) 0.008
UC Clinical remissiona (n = 25) Active diseaseb (n = 20) p value
FC < 50 μg/g 4 (16 %) 2 (10 %) 0.678
FC < 250 μg/g 12 (48 %) 6 (30 %) 0.359
FC < 1000 μg/g 23 (92 %) 10 (50 %) 0.002
CRP < 5 mg/L 20 (80 %) 15 (75 %) 0.731
CD Crohn’s disease, CRP C-reactive protein, FC fecal calprotectin, UC ulcerative colitis
a Abbreviated Pediatric Crohn’s Disease Activity Index <10 or Pediatric Ulcerative Colitis Activity Index <10
bAbbreviated Pediatric Crohn’s Disease Activity Index <10 or Pediatric Ulcerative Colitis Activity Index <10
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37 %) of variation in symptoms can be explained by variation
in inflammation. This may partly be explained by the fact that
disease activity was relatively mild in our study population.
Indeed, the majority of patients were in clinical remission.
Consequently, the relatively small variation in the total clinical
indices scores potentially decreased the strength of the corre-
lation. However, the distribution of disease activity in our
study appears to be similar to that of large cohort studies on
the clinical course of pediatric IBD [22, 11]. Thus, the corre-
lation that we found is more likely to reflect the relationship
between symptoms and the degree of intestinal inflammation
in daily practice, compared to previously reported correlation
coefficients from studies that also included patients at the time
of diagnosis [9, 1, 4].
The lack of correlation between levels of CRP and
clinical disease activity in patients with UC can be ex-
plained by the poor sensitivity of CRP for endoscopically
active UC [29, 25]. The reason why CRP seems to be less
accurate in UC compared to CD is unclear, although it
may be explained by the fact that in UC, inflammation
is limited to the mucosa, in contrast to the transmural
inflammation in CD [38]. Moreover, serum levels of IL-
6, the main mediator of the production of CRP, are shown
to be higher in children with CD compared to those with
UC [5].
In our study, a large proportion of patients had elevated
serum and fecal markers of inflammation, despite the com-
plete absence of clinical symptoms. This may be partly ex-
plained by the suboptimal accuracy of these biomarkers.
However, in our opinion, these elevated inflammatory
markers in patients with quiescent IBD probably reflect ongo-
ing IBD activity in the majority of patients. Indeed, many
studies have shown that children and adults with IBD in clin-
ical remission have ongoing inflammation on endoscopy [39,
23, 8, 14, 41, 40].
The discrepancy between clinical symptoms and biochem-
ical markers of inflammationmay have important implications
for the management of IBD. Since symptoms are only weakly
associated with the underlying inflammatory process, one
could argue whether it should be a prerequisite that a thera-
peutic agent reduces both clinical symptoms and the underly-
ing inflammation. Perhaps these are two distinct aims, poten-
tially with two distinct interventions or treatment strategies.
Future research is required to determine the optimal strategy to
attain both goals.
Fig. 2 a Fecal calprotectin and b C-reactive protein levels by clinical
disease activity as assessed by PUCAI
Table 3 Correlation between the clinical indices total scores, individual
components, and biochemical markers of disease activity
CD (aPCDAI) FC (rs) CRP (rs)
Abdominal paina 0.133 0.180
Stools (per day)a 0.156 0.020
Patient functioninga 0.177 0.242*
Weighta 0.185 0.052
Abdominal examinationa 0.231* 0.326*
Perirectal diseasea 0.232* 0.023
Total aPCDAI scorea 0.324* 0.275*
UC (PUCAI) FC (rs) CRP (rs)
Abdominal paina 0.147 −0.039
Rectal bleedinga 0.192 0.057
Stool consistency of most stoolsa 0.203 0.121
Number of stool per 24ha 0.270 0.140
Nocturnal stools
(any episodes causing wakening)b
0.239 0.190
Activity levela 0.461* −0.008
Total PUCAI scorea 0.361* 0.005
aPCDAI abbreviated Pediatric Crohn’s Disease Activity Index, CD
Crohn’s disease, CRP C-reactive protein, FC fecal calprotectin, PUCAI
Pediatric Ulcerative Colitis Activity Index, UC ulcerative colitis
*Significant correlation (p < 0.05)
a Spearman’s rank correlations
b Point-biserial correlation
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The strength of our study is that we included a random
sample of children and adolescents with an established
diagnosis of IBD. Consequently, our findings are likely
to reflect the relationship between disease activity and
the degree of intestinal inflammation in daily practice. A
weakness is that we did not assess disease activity using
endoscopy with histology, since in our practice, endosco-
py is not routinely performed to monitor disease activity
during follow-up.
In conclusion, in this study of children with previously
diagnosed IBD, clinical disease activity was only weakly as-
sociated with inflammatory markers FC and CRP. This may
implicate that clinical symptoms and inflammatory markers
represent two distinct aspects of disease activity and should
be considered separately in clinical decision-making.
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